Brief: Hepion Pharma Says Results From Translational Research Study In Which CRV431 Decreased Formation Of A Novel Class Of Human Blood Platelets
02/12/2020 13:25
Dec 2 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS - RESULTS FROM TRANSLATIONAL
RESEARCH
STUDY IN WHICH CRV431 DECREASED FORMATION OF A NOVEL CLASS OF
HUMAN BLOOD PLATELETS
* HEPION PHARMACEUTICALS INC - CRV431 SEEMINGLY HAD NO
SIGNIFICANT
EFFECT ON PLATELET AGGREGATION
* HEPION - TREATMENT WITH CRV431 AT PHARMACOLOGICALLY
RELEVANT
CONCENTRATIONS DECREASED MEMBRANE EXPOSURE OF
PHOSPHATIDYLSERINE, BY UP TO 49%
Source text for Eikon: ID:
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement